SEC Form 4 · accession 0001140361-16-089152
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Dec 6, 2016
Accepted (ET)
Dec 8, 2016 · 7:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $26.27 | Dec 6, 2016 | A | 209,000 | A | — | Dec 5, 2026 | Common Stock | 209,000 | 209,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.